Peptide profile
Published Data as of
In mice with dextran sodium sulfate (DSS) colitis, nanoparticle KPV protected against inflammatory and histologic changes compared with DSS alone.1 In animal studies, it matched free KPV at a 12,000-fold lower concentration.1 PepBank's records hold 57 findings in animals and 67 laboratory findings for KPV, and no registered trials.2 The PepBank regulatory record lists KPV as not approved for any use.3
KPV is the Lys-Pro-Val tail of alpha-melanocyte-stimulating hormone (alpha-MSH), the fragment written as alpha-MSH (11-13). In febrile rabbits, this tripeptide given into the brain ventricles brought fever down in a dose-related way.7 In those rabbits it cut fever less than alpha-MSH (8-13) and more than alpha-MSH (10-13).7
In febrile rabbits, lysine-proline-valine brought fever down when it was given centrally and also when it was given peripherally.8 In the same rabbits it was less potent than the parent molecule, full-length alpha-MSH (1-13).7,8
In mice, oral KPV reduced the incidence of dextran sodium sulfate (DSS) colitis. The same oral peptide reduced the incidence of TNBS-induced colitis in mice.4 In mice with DSS or TNBS colitis, oral KPV lowered expression of pro-inflammatory cytokines.4
In mice with DSS colitis, KPV treatment led to earlier recovery and significantly stronger regain of body weight.9 It significantly reduced inflammatory infiltrates in the colon and myeloperoxidase activity in colonic tissue in those mice.9
In mice with CD45RB(hi) transfer colitis, KPV treatment led to recovery and regain of body weight. It also reduced inflammatory changes in colon histology in these mice.9 In mice with a nonfunctional melanocortin-1 receptor and DSS colitis, KPV rescued all treated animals from death.9
In mice with DSS colitis, nanoparticle KPV (NP-KPV) protected against inflammatory and histologic changes compared with DSS alone.1 In animal studies, that nanoparticle form worked about as well as free KPV at a 12,000-fold lower concentration.1
In a mouse model of ulcerative colitis, hyaluronic acid-functionalized KPV nanoparticles (HA-KPV-NPs) sped up mucosal healing and eased inflammation.5 In the same mice, oral HA-KPV-NP/hydrogel worked much better than the KPV-NP/hydrogel system.5
In mice with ulcerative colitis, the oral coated nanoparticles in hydrogel prevented mucosa damage better than the KPV-NP/hydrogel system. They also downregulated tumor necrosis factor alpha (TNF-alpha) more strongly in those mice.5 In mice with DSS-induced ulcerative colitis, KPV nanoparticles without cyclosporine A also had marked therapeutic effects.10
| Delivery form | What the animal study reported |
|---|---|
| Oral peptide (in mice) | In mice, oral KPV reduced the incidence of DSS-induced colitis.4 |
| Nanoparticles with polysaccharide hydrogel (in mice) | In mice with DSS colitis, NP-KPV protected against inflammatory and histologic changes.1 |
| Hyaluronic acid-coated nanoparticles (in mice) | In a mouse model of ulcerative colitis, HA-KPV-NPs sped up mucosal healing.5 |
| Rectal KPV/SH-PGA hydrogel (in rats) | In rats with TNBS-induced colitis, it attenuated the disease activity index score.6 |
| PMSP double-network hydrogel (in rats) | In rats with TNBS-induced colitis, PMSP-KPV recovered the colonic epithelial barrier.11 |
In rats with TNBS-induced colitis, a rectal KPV/SH-PGA hydrogel clearly attenuated body weight loss and the disease activity index score.6 In the same rats, the hydrogel treatment prevented colon shortening.6
In rats with TNBS colitis, the hydrogel treatment lowered the colonic myeloperoxidase level.6 In those rats, the epithelial barrier of the colon recovered after the treatment.6
In rats with TNBS-induced colitis, KPV eased colitis significantly better when the peptide was given with the PMSP hydrogel.11 In those rats, PMSP-KPV recovered the colonic epithelial barrier and markedly increased the abundance of beneficial gut microorganisms.11
PepBank's records hold no result from a study in people for KPV.2 As of November 15, 2026, the record shows 0 publications and 0 findings in people.2
The record holds 16 publications with 57 findings in animals for KPV.2 The record also holds 18 publications with 67 laboratory findings in cells or tissue, sorted into PepBank's evidence classes.2 The record holds 0 publications and 0 findings from computer models.2
The trial registry records in PepBank hold no registered trial that tests KPV.2 The PepBank regulatory record lists KPV as not approved for any use in all places in the record, as of October 30, 2026.3
KPV is in PepBank's list of peptides with 28 studies that gave the peptide and 124 results from them.2 The KPV studies page holds 0 findings in people and 57 findings in animals.2
PepBank's records hold no result from a study in people for KPV.2 As of November 15, 2026, the record shows 0 publications with findings in people and no registered trial that tests the peptide.2 The record holds 57 findings in animals and 67 laboratory findings in cells or tissue.2
The PepBank regulatory record lists KPV as not approved for any use in all places in the record, as of October 30, 2026.3 The research record behind it is animal and laboratory work. It has 57 findings in animals and 67 laboratory findings in cells or tissue. It has no registered trials.2
A mouse study points to the peptide transporter PepT1.12 In wild-type mice with AOM/DSS-induced colitis-associated cancer, KPV prevented carcinogenesis.12 In PepT1-knockout mice, KPV did not trigger the inhibitory effect on tumorigenesis seen in wild-type mice. So in those mice the effect depended on the transporter.12
In mice with crystal-induced peritonitis, systemic KPV significantly reduced polymorphonuclear leukocyte accumulation in the peritoneal cavity.13 KPV also had anti-inflammatory effects in mice with IL-1beta-induced peritonitis.13 In rabbits with corneal epithelial abrasion, topical KPV significantly reduced the percent of epithelial defect remaining compared with controls.14
In mice, the MC3/4-R antagonist SHU9119 did not block the antimigratory effect of KPV.13 Its anti-inflammatory properties also showed up in mice with a nonfunctional MC1-R.13 In rabbits with corneal abrasion, pre-treatment with the nitric oxide synthase inhibitor L-NAME inhibited the wound healing effect of KPV.14
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated